Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAT9001 in Severe Hypertriglyceridemia (AMPLIFY)
NCT04662528Phase 3Withdrawn
- Sponsor
- Matinas BioPharma
- Start
- Jun 2021
- Primary completion
- Aug 2022
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in severe hypertriglyceridemia (SHTG) comparing Placebo with MAT9001 (2 arms). Primary endpoint: The percent change from baseline to end of study for MAT9001 versus Placebo at 12 weeks. Planned start Jun 2021; status: withdrawn.
02
Drugs
MAT9001
03
Conditions
severe hypertriglyceridemia (SHTG)
Beyond the preview
Go deeper on NCT04662528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04662528.